

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5681390/publications.pdf>

Version: 2024-02-01

218
papers

33,866
citations

7561

77
h-index

3911

177
g-index

226
all docs

226
docs citations

226
times ranked

21020
citing authors

#	ARTICLE	IF	CITATIONS
1	Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?. <i>Gastroenterology</i> , 2023, 165, 5-10.	0.6	59
2	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	2.4	9
3	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.	2.4	41
4	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2022, 76, 265-274.	1.8	24
5	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
6	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2022, 76, 506-517.	1.8	49
7	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.	1.8	66
8	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688.	0.6	53
9	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	2.6	20
10	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.	1.8	74
11	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. <i>Hepatology</i> , 2022, 76, 456-468.	3.6	22
12	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.3	7
13	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012.	1.8	54
14	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. <i>Biomedicines</i> , 2022, 10, 699.	1.4	7
15	Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis. <i>Hepatology</i> , 2022, 76, 1360-1375.	3.6	30
16	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
17	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	3.6	15
18	An international survey on patterns of practice in NAFLD and expectations for therapiesâ€”The POPâ€”NEXT project. <i>Hepatology</i> , 2022, 76, 1766-1777.	3.6	7

#	ARTICLE	IF	CITATIONS
19	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477.	2.6	31
20	Cliniciansâ€™ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2707.	1.0	1
21	Breakthroughs in therapies for NASH and remaining challenges. <i>Journal of Hepatology</i> , 2022, 76, 1263-1278.	1.8	66
22	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617.		2
23	The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis. <i>Journal of Molecular Medicine</i> , 2022, 100, 1039-1042.	1.7	1
24	Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1020-1029.e7.	2.4	21
25	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	13.9	833
26	Liver Stiffness by Transient Elastography to Detect Portoâ€™Sinusoidal Vascular Liver Disease With Portal Hypertension. <i>Hepatology</i> , 2021, 74, 364-378.	3.6	40
27	coreNASH: Multiâ€™stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. <i>Hepatology Communications</i> , 2021, 5, 774-785.	2.0	3
28	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
29	Disease burden and economic impact of diagnosed nonâ€™alcoholic steatohepatitis in five European countries in 2018: A costâ€™ofâ€™illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	1.9	76
30	Yet more evidence that MAFLD is more than a name change. <i>Journal of Hepatology</i> , 2021, 74, 977-979.	1.8	25
31	European â€™NAFLD Preparedness Indexâ€™ â€™ Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021, 3, 100234.	2.6	27
32	Ã–konomische Kosten und Gesundheitsfolgen von nicht-alkoholischer Fettleberhepatitis in den EU5 LÃ¤ndern. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.2	0
33	Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. <i>Clinical Liver Disease</i> , 2021, 17, 398-400.	1.0	2
34	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486.	0.6	101
35	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	2.6	6
36	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021, 75, 1292-1300.	1.8	27

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 889-902.	3.7	26
38	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
39	Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <i>Nature Medicine</i> , 2021, 27, 1825-1835.	15.2	98
40	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939.	5.8	17
41	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.	13.9	284
42	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021, 70, 2359-2372.	6.1	56
43	Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Nutrition</i> , 2021, 8, 774030.	1.6	20
44	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	1.8	123
45	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	2.4	104
46	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020, 88, 105889.	0.8	80
47	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 828-838.	1.8	52
48	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 998-1007.	0.8	8
49	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 627-635.	1.8	84
50	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 59-66.	0.5	17
51	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	0.8	25
52	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	0.8	71
53	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	205
54	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985.	3.7	142

#	ARTICLE	IF	CITATIONS
55	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020, 2, 100142.	2.6	53
56	Clinical endpoints are necessary in the interim analysis of REGENERATE – Authors' reply. <i>Lancet</i> , The, 2020, 396, 663-664.	6.3	0
57	The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309.	1.8	45
58	A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2020, 37, 4627-4640.	1.3	4
59	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. <i>Nature Metabolism</i> , 2020, 2, 514-531.	5.1	31
60	Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. <i>Scientific Reports</i> , 2020, 10, 3850.	1.6	39
61	Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed. <i>Hepatology</i> , 2020, 71, 1146-1149.	3.6	0
62	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	0.6	1,840
63	Genecriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905.	3.6	227
64	Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. <i>Gastroenterology</i> , 2020, 159, 422-427.e1.	0.6	15
65	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	1.8	2,171
66	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	1.8	279
67	Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. <i>Cell Reports Medicine</i> , 2020, 1, 100154.	3.3	23
68	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020, 15, e0242306.	1.1	10
69	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.5	11
70	Pharmacological Options for NASH. , 2020, , 309-327.		0
71	Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham Score. <i>Hepatology</i> , 2019, 69, 1453-1463.	3.6	41
72	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	0.8	105

#	ARTICLE	IF	CITATIONS
73	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 193-203.	1.9	112
74	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019, 1, 188-198.	2.6	86
75	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. <i>Transplantation</i> , 2019, 103, 28-38.	0.5	28
76	External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. <i>GastroHep</i> , 2019, 1, 146-153.	0.3	3
77	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019, 70, 1841-1855.	3.6	64
78	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	3.6	226
79	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
80	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 393-402.	0.8	12
81	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e86-e94.	0.9	53
82	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320.	1.9	15
83	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 616-629.e26.	2.4	91
84	The journey of a patient with biopsy-proven non-alcoholic steatohepatitis (NASH) – results from a real-world study. , 2019, 57, .		0
85	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 569-577.	0.8	15
86	Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 384-391.	0.8	13
87	The painful reality of end-stage liver disease in NASH. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 8-10.	3.7	8
88	Genecriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study. <i>Journal of Hepatology</i> , 2018, 68, S1-S2.	1.8	10
89	Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D). <i>American Journal of Gastroenterology</i> , 2018, 113, 443-445.	0.2	2
90	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012.	3.6	125

#	ARTICLE	IF	CITATIONS
91	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	3.6	528
92	A critical review of endpoints for non-cirrhotic NASH therapeutic trials. <i>Journal of Hepatology</i> , 2018, 68, 353-361.	1.8	58
93	NAFLD: The evolving landscape. <i>Journal of Hepatology</i> , 2018, 68, 227-229.	1.8	11
94	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127.	1.9	28
95	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	0.6	253
96	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370.	1.8	51
97	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	1.8	1,157
98	The EPOS staging system is a reproducible 7-tier fibrosis score for NAFLD adapted both to glass slides and digitized images (e-slides). <i>Journal of Hepatology</i> , 2018, 68, S553.	1.8	8
99	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
100	Non-pharmacological interventions in non-alcoholic fatty liver disease patients. <i>Liver International</i> , 2017, 37, 90-96.	1.9	34
101	Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S2-S3.	1.8	9
102	Screening studies of transient elastography and FibroTest in the general population. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 246.	3.7	1
103	Back to Byzance: Querelles byzantines over NASH and fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 1134-1136.	1.8	16
104	Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials. <i>Journal of Hepatology</i> , 2017, 66, S54.	1.8	22
105	Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2017, 66, S159-S160.	1.8	2
106	Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S110-S111.	1.8	3
107	Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S594-S595.	1.8	4
108	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.2	524

#	ARTICLE	IF	CITATIONS
109	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. PLoS ONE, 2017, 12, e0189436.	1.1	13
110	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 428-432.	0.6	19
111	Arterial hypertension as an uninvited player in hepatic stiffness?. American Journal of Physiology - Renal Physiology, 2016, 311, C942-C944.	1.6	3
112	Novel Pharmacotherapy Options for NASH. Digestive Diseases and Sciences, 2016, 61, 1398-1405.	1.1	35
113	507 APRI and FIB-4 Index Scores Can Enrich for Subjects With Fibrotic Non-Alcoholic Steatohepatitis (NASH) in Clinical Trials - The CENTAUR Trial Data. Gastroenterology, 2016, 150, S1037-S1038.	0.6	1
114	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemporary Clinical Trials, 2016, 47, 356-365.	0.8	178
115	Fatty liver is an independent predictor of early carotid atherosclerosis. Journal of Hepatology, 2016, 65, 95-102.	1.8	91
116	NAFLD and liver transplantation: Current burden and expected challenges. Journal of Hepatology, 2016, 65, 1245-1257.	1.8	352
117	Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease". Journal of Hepatology, 2016, 65, 1267-1268.	1.8	2
118	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Alimentary Pharmacology and Therapeutics, 2016, 44, 877-889.	1.9	70
119	Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis. Journal of Hepatology, 2016, 64, S294-S295.	1.8	16
120	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 2016, 3, e000075.	1.1	90
121	When the journey from obesity to cirrhosis takes an early start. Journal of Hepatology, 2016, 65, 249-251.	1.8	8
122	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor α and β , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology, 2016, 150, 1147-1159.e5.	0.6	847
123	Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. PLoS ONE, 2016, 11, e0163276.	1.1	26
124	Hepatic and Extrahepatic Malignancies in NAFLD. , 2016, , 271-290.		0
125	Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. BMJ Open, 2015, 5, e010017.	0.8	9
126	PWE-120 High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (\geq 65 years) with nafld. Gut, 2015, 64, A265.1-A265.	6.1	0

#	ARTICLE	IF	CITATIONS
127	Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 30-36.	1.0	42
128	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. <i>Hepatology</i> , 2015, 61, 1041-1055.	3.6	102
129	Non-alcoholic fatty liver "Perhaps not so benign. <i>Journal of Hepatology</i> , 2015, 62, 1002-1004.	1.8	38
130	Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015, 62, S65-S75.	1.8	228
131	Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 763-771.e6.	2.4	65
132	Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 992-999.e2.	2.4	26
133	Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. <i>PLoS ONE</i> , 2015, 10, e0134302.	1.1	14
134	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015, 21, 5647.	1.4	13
135	Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. <i>Digestive Diseases</i> , 2014, 32, 586-596.	0.8	10
136	Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1209-1222.	1.9	328
137	Hepatic molecular effects of rosiglitazone in human nonalcoholic steatohepatitis suggest long-term proinflammatory damage. <i>Hepatology Research</i> , 2014, 44, 1241-1247.	1.8	16
138	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest [®] , [†]) and transient elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 60, 706-714.	1.8	101
139	P832 CLINICAL VALIDATION OF THE FLIP ALGORITHM AND SAF SCORE IN NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2014, 60, S348.	1.8	4
140	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 1220-1227.	1.8	25
141	Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1081-1093.	1.9	27
142	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest [®]) and elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 61, 994-1003.	1.8	42
143	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	5.8	478
144	The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 165-178.	1.0	34

#	ARTICLE	IF	CITATIONS
145	Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1724-1730.e5.	2.4	41
146	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014, 232, 99-109.	0.4	113
147	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI" est fini? Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 432-439.	0.7	10
148	Targeting non-alcoholic fatty liver disease through 11- β HSD1 inhibition. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 354-356.	5.5	4
149	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 58, 1941-1952.	3.6	355
150	Pharmacological agents for NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 676-685.	8.2	58
151	Pharmacological agents for nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2013, 7, 833-841.	1.9	2
152	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013, 59, 859-871.	1.8	304
153	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013, 59, 550-556.	1.8	421
154	104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Journal of Hepatology</i> , 2013, 58, S46.	1.8	9
155	Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 675-683.	1.8	134
156	Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard. <i>Journal of Hepatology</i> , 2013, 58, 928-935.	1.8	151
157	Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 655-656.	1.9	2
158	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2013, 159, 370.	2.0	2
159	Randomized Study of Asunaprevir plus Pegylated Interferon- α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893.	0.6	44
160	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. <i>World Journal of Gastroenterology</i> , 2013, 19, 57.	1.4	104
161	The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 262-269.	0.8	30
162	5 THE EMERGING IMPACT OF HEPATOCELLULAR CARCINOMA ARISING ON A BACKGROUND OF NAFLD. <i>Journal of Hepatology</i> , 2012, 56, S3.	1.8	2

#	ARTICLE	IF	CITATIONS
163	Treatment of NASH with ursodeoxycholic acid: Pro. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, S41-S45.	0.7	28
164	Touching some firm ground in the epidemiology of NASH. Journal of Hepatology, 2012, 56, 23-25.	1.8	16
165	Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: A step toward the truth in the absence of a gold standard. Journal of Hepatology, 2012, 56, 541-548.	1.8	76
166	A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. Journal of Hepatology, 2012, 57, 376-383.	1.8	57
167	Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population. Journal of Hepatology, 2012, 57, 541-548.	1.8	65
168	Performances of Elasto-FibroTest®, a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 455-463.	0.7	16
169	Liver Biopsy Analysis Has a Low Level of Performance for Diagnosis of Intermediate Stages of Fibrosis. Clinical Gastroenterology and Hepatology, 2012, 10, 657-663.e7.	2.4	97
170	A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology, 2012, 55, 419-428.	3.6	141
171	Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data. PLoS ONE, 2012, 7, e30325.	1.1	117
172	FibroTest® and Fibroscan® performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 720-730.	0.7	26
173	Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 23-28.	0.7	54
174	A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. Journal of Hepatology, 2011, 54, 1011-1019.	1.8	278
175	Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World Journal of Gastroenterology, 2011, 17, 3377.	1.4	244
176	What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regulatory Toxicology and Pharmacology, 2011, 60, 290-295.	1.3	32
177	Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Current Hepatitis Reports, 2011, 10, 87-97.	0.3	51
178	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterology, 2011, 11, 39.	0.8	58
179	Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology, 2011, 54, 344-353.	3.6	617
180	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?. Expert Review of Gastroenterology and Hepatology, 2011, 5, 279-289.	1.4	55

#	ARTICLE	IF	CITATIONS
181	The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test. <i>American Journal of Gastroenterology</i> , 2011, 106, 1853.	0.2	2
182	Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal Studies. <i>Antiviral Therapy</i> , 2010, 15, 617-631.	0.6	56
183	Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. <i>Hepatology</i> , 2010, 51, 445-453.	3.6	315
184	Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues. <i>Hepatology</i> , 2010, 52, 2206-2215.	3.6	65
185	Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). <i>BMC Gastroenterology</i> , 2010, 10, 40.	0.8	173
186	A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. <i>Human Pathology</i> , 2010, 41, 1178-1185.	1.1	11
187	ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 388-396.	0.9	33
188	Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. <i>Hepatology</i> , 2008, 48, 2089-2089.	3.6	94
189	Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. <i>Gastroenterologie Clinique Et Biologique</i> , 2008, 32, 8-21.	0.9	39
190	Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial. <i>Gastroenterology</i> , 2008, 135, 100-110.	0.6	575
191	Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2008, 49, 831-844.	1.8	364
192	Screening for Liver Fibrosis by Using a Noninvasive Biomarker in Patients With Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 828-831.	2.4	58
193	Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers. <i>PLoS ONE</i> , 2008, 3, e3857.	1.1	75
194	An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load. <i>PLoS ONE</i> , 2008, 3, e2573.	1.1	64
195	Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 207-218.	1.9	52
196	Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. <i>Clinical Chemistry</i> , 2007, 53, 1615-1622.	1.5	227
197	Meta-analyses of FibroTest diagnostic value in chronic liver disease. <i>BMC Gastroenterology</i> , 2007, 7, 40.	0.8	268
198	Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 733-739.	1.9	83

#	ARTICLE	IF	CITATIONS
199	The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. <i>Journal of Hepatology</i> , 2006, 44, 1175-1185.	1.8	50
200	Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006, 6, 34.	0.8	245
201	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006, 6, 6.	0.8	378
202	A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2006, 52, 1887-1896.	1.5	210
203	The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. <i>Comparative Hepatology</i> , 2005, 4, 10.	0.9	297
204	NASH: a hidden and silent fibroser finally revealed?. <i>Journal of Hepatology</i> , 2005, 42, 12-14.	1.8	30
205	Biomarkers as a first-line estimate of injury in chronic liver diseases: Time for a moratorium on liver biopsy?. <i>Gastroenterology</i> , 2005, 128, 1146-1148.	0.6	40
206	Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2005, 128, 1898-1906.	0.6	1,703
207	Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. <i>Clinical Chemistry</i> , 2004, 50, 1344-1355.	1.5	286
208	Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. <i>Comparative Hepatology</i> , 2004, 3, 8.	0.9	311
209	The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2004, 39, 862-863.	3.6	111
210	Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003, 38, 75-85.	3.6	531
211	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	1.8	401
212	Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 222-230.	1.8	322
213	Viral hepatitis C. <i>Lancet, The</i> , 2003, 362, 2095-2100.	6.3	758
214	Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. <i>Hepatology</i> , 2002, 35, 1485-1493.	3.6	414
215	Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2001, 34, 730-739.	1.8	666
216	Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. <i>Lancet, The</i> , 2001, 357, 1069-1075.	6.3	1,316

#	ARTICLE	IF	CITATIONS
217	Liver fibrosis in overweight patients. <i>Gastroenterology</i> , 2000, 118, 1117-1123.	0.6	861
218	Apolipoprotein A1 and hepatic fibrosis. <i>Journal of Hepatology</i> , 1995, 22, 107-10.	1.8	10